Figure 1: Clinical Trial Design

- **V = OC-DC Vaccine**, Bev = Bevacizumab at 10mg/kg in Cohort 2, Bevacizumab at 15mg/kg in Cohort 3
- Cy = Cyclophosphamide at 200 mg/m^2^, * = Prevnar
- CT = chest/abdomen/pelvis
- IA = Immune Assessment
- T = T cell Monitoring

Follow Up every 6 months for 5 years